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ABSTRACT
Objective: This study was performed to evaluate the association of body
mass index (BMI) with the incidence of cardiometabolic risk factors in
ambulatory care electronic medical records (EMRs) over 5 years or more.
Design: A retrospective cohort of normal versus obese patients.
Subjects: Subjects 18 years were identiﬁed between 1996 and 2005.
Measurements: Patients were categorized as either normal weight (18 kg/
m2 < BMI  27 kg/m2) or obese (BMI > 27 kg/m2) based on baseline BMI
(measured 395 days or more after ﬁrst EMR activity). Outcomes included
development, at least 180 days after the ﬁrst BMI reading date, of four
cardiometabolic risk factors (elevated triglycerides, low high-density lipo-
protein cholesterol [HDL-C], hypertension, or type 2 diabetes) determined
from ICD-9 code, prescribed drug, or biometric reading. Logistic regression
estimated the odds of developing cardiometabolic risk factors, alone and
combined for normal versus obese patients forward for at least 5 years.
Results: Seventy-one percent were female, mean age was 43.5 years, and
37.6% had a baseline BMI > 27 kg/m2. Comparing obese versus normal
weight patients, adjusted odds ratios for the incidence of elevated triglyc-
erides, hypertension, diabetes, and low HDL-C were 2.1 (95% conﬁdence
interval [95% CI] 1.9–2.3), 2.2 (95% CI 2.1–2.4), 2.3 (95% CI 2.0–2.7),
and 2.2 (95% CI 2.0–2.4), respectively. Adjusted odds ratios of developing
one and all four new risk factors were 1.9 (95% CI 1.8–2.1) and 7.9 (95%
CI 5.9–10.5), respectively.
Conclusion: Obese patients are approximately twice as likely to develop
cardiometabolic risk factors compared with those having normal weight
over 5 or more years.
Keywords: ambulatory care, body mass index, cardiometabolic risk, elec-
tronic medical records, long-term risk management.
Introduction
Obesity is associated with insulin resistance, and the combina-
tion of obesity and reduced glucose tolerance is an important
underlying risk factor to the development of dyslipidemia [1]. A
recent analysis of the Medical Expenditure Panel Survey (MEPS)
found that diabetes and dyslipidemia occur much more fre-
quently in obese patients than in nonobese patients. Relative to
nonobese patients, the prevalence of diabetes plus dyslipidemia
was two and a half times higher in obese patients aged 70–79
(prevalence ratio = 2.54), and almost seven times higher in obese
subjects aged 20–29 (prevalence ratio = 6.94) [2]. Obesity and
weight gain are also associated with the development of hyper-
tension. Among adult women, weight at age 18 and weight gain
after that age were positively associated with development of
hypertension (P-value for trend <0.001) [3].
Several other studies have demonstrated the association
between obesity and development of other components of cardi-
ometabolic risk [4–8]. Nevertheless, most studies report cross-
sectional data on coexistence of cardiometabolic risk factors with
weight. Further, most of these studies have been conducted in
small populations or as a randomized controlled trial, and are
not representative of the United States as a whole. Therefore,
there is a need to investigate the effect of existing obesity on the
incidence of cardiometabolic risk factors over time using a large
national database in a real-world setting.
The primary aim of this study was to investigate the relation-
ship between body mass index (BMI), measured at a baseline,
and the subsequent development of cardiometabolic risk factors
in broadly representative ambulatory care settings. Speciﬁcally,
the study examined the progression toward cardiometabolic risk
factors over a period of at least 5 to 8.5 years using a large,
nationally representative electronic medical record (EMR)
database.
Methods
Data Source
This study utilized data from the General Electric Centricity
Electronic Medical Record (GE EMR) research database (GE
Healthcare, Waukesha, WI). The GE EMR, a deidentiﬁed, Health
Insurance Portability and Accountability Act compliant data-
base, is comprised of longitudinal patient data and includes, but
is not limited to, demographic information, vital signs, labora-
tory orders and results, medication list entries and prescribed
medications, and diagnoses or problems.
Over 100 physician practice sites located in 35 states that
participate in the Medical Quality Information Consortium
submit GE Centricity EMR data. Consortium members represent
a variety of ambulatory care practice types including solo prac-
tices, group practices, community clinics, academic medical
centers, and large integrated delivery networks. At the time of the
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study (1996–2005), the GE EMR held data on 3.3 million
patients contributed by over 5000 physicians. Data are centrally
collected and undergo a quality control process to remove or
correct invalid data.
An analysis of patients in the EMR database in 2005 indi-
cated that the population is similar to the US population based
on the 2005 US Census estimates, data from the National Health
and Nutrition Examination Survey 2003–2004, and the National
Health Interview Survey 2005 [9]. Nevertheless, the GE EMR
has a higher representation of women, and patient data are
available for only 35 of 50 US states with a higher representation
of northeastern and midwestern states.
Study Population
Subjects with clinical activity were identiﬁed from the GE EMR
database from 1996 to 2005. Subjects were included in the
analysis if 18 years of age or older on or before the patient’s ﬁrst
activity date with at least one BMI reading measured 395 days or
more after the ﬁrst activity date (deﬁned as the date the patient
ﬁrst became active in the EMR for a speciﬁc ofﬁce site indicating
an interaction with the physician such as an ofﬁce visit, a tele-
phone consult, or a prescription order).
The ﬁrst BMI reading recorded after 395 days of activity was
deﬁned as the baseline BMI and the study index date for the
patient. A preindex BMI window of 395 days or more was
included to allow for identiﬁcation of baseline risk factors which
may have only been recorded in the EMR on an annual basis. An
additional 30-day period was added to a 1 year window to allow
time for a prescription which had expired at the pharmacy to be
reordered by the physician. To be included in the study, a subject
must have had an EMR activity recorded at 5 years or more after
the index date. Thus, all subjects were observed for a minimum
of 5 years to ensure that the patient continued to be cared for by
the EMR provider. Patients with an index BMI of less than
18 kg/m2 (underweight) were excluded, as were patients with any
indication of elevated triglycerides, low high-density lipoprotein
cholesterol (HDL-C), hypertension, or type 2 diabetes prior to
index date.
Study Time Frame
The study period was from January 1996 through June of 2005.
The observation window for each patient was 395 days before
the index BMI date or the ﬁrst activity date, whichever was
greater, through 5 years post–index date or their last activity
date, whichever was greater. Thus, all study subjects had between
5 and 8.5 years of GE EMR follow-up postbaseline period.
Study Variables
Study outcome variables were the incidence of one or more of
four cardiometabolic risk factors, high triglycerides, low HDL-C,
hypertension, or type 2 diabetes, as determined from clinical
diagnosis, pharmacotherapy, or biometric reading. Patients were
deﬁned as having elevated triglycerides if they had a triglyceride
reading equal to or greater than 150 mg/dl, were taking ﬁbrates,
or had an ICD-9 code of 272.1. Low HDL-C was identiﬁed if a
patient had a HDL-C value of less than 40 mg/dl in men or less
than 50 mg/dl in women, or was on niacin. Patients were con-
sidered to have hypertension if there were at least two recorded
systolic BP readings equal to or greater than 130 mmHg or
diastolic blood pressures equal to or greater than 85 mmHg
within 395 days, or had been prescribed an angiotensin-
converting enzyme inhibitor, angiotensin receptor blocker,
calcium channel blocker, beta-blocker, thiazide diuretic, vasodi-
lator, or ﬁxed dose antihypertensive combination, or had an
ICD-9 code of 401.x. Patients were categorized as diabetic if they
had a fasting blood glucose level equal to or above 126 mg/dl, or
if the patient was treated with sulfonylureas, metformin, thiazo-
lidinediones, meglitinides, alpha glucosidase inhibitors, or ﬁxed
dose antidiabetic combinations, or had an ICD-9 code for type 2
diabetes of 250.x0 or 250.x2. Biometric criteria for the selection
of patients with hypertension, low HDL-C, and high triglycerides
were based on the third report of the National Cholesterol Edu-
cation Program Adult Treatment Panel (NCEP-ATP III) [10].
With the exception of blood pressures in which two elevated
readings were required, the occurrence of a single out-of-range
laboratory value, single diagnosis code, or one prescription drug
order to treat the related condition was used to identify the
presence of a risk factor.
Cardiometabolic risk factors were considered to be incident if
they were documented more than 180 days after the index date
and were not documented before the index date or within 180
days post–index date. Incident risk factors were identiﬁed both as
individual risk factors and as the count of risk factors ranging
from 0 to 4. In the case of availability of multiple measurements
of a risk factor in the follow-up period, only the ﬁrst indicator of
a risk factor in the GE EMR data was considered.
The primary independent variable in this study was the base-
line BMI, which was calculated from the patients’ height and
weight measurements, and categorized as either BMI  27 kg/m2
or BMI > 27 kg/m2. This cutoff acknowledged that weight-loss
drugs are approved by the US Food and Drug Administration as
adjuncts to diet and exercise in patients with a BMI of 30 kg/m2
or greater, or a BMI > 27 kg/m2 for patients with one or more
concomitant risk factors, including hypertension, dyslipidemia,
and type 2 diabetes [11]. Thus, in calculating the odds ratios
(ORs) for the outcome measure, a BMI > 27 kg/m2 was used as
the cutoff. Although the term “obesity” is generally used for
those with a BMI greater than 30 kg/m2, for ease of communi-
cation we have termed the patients in this study with a baseline
BMI > 27 kg/m2 as obese, recognizing that our terminology
differs from the technical deﬁnition. Nevertheless, over half of
the patients in the BMI > 27 kg/m2 group (56%) were technically
obese with a baseline BMI > 30 kg/m2.
NCEP [10] and IDF [12] guidelines use waist circumference
as a measure of central or abdominal obesity. Waist circumfer-
ence is rarely available in clinical data, BMI and waist circum-
ference are highly correlated and each independently contributes
a signiﬁcant risk for cardiometabolic risk factors and chronic
diseases [7,8,13,14]. A recent publication examining waist cir-
cumference, BMI, and their association with cardiometabolic
risk demonstrated that increased waist circumference and BMI
were equally strong predictors of risk [15]. Thus, BMI, calculated
from height and weight information in the EMR, was used as a
proxy measure of obesity.
Additional independent variables that were collected included
gender; age at index date (categorized as 18–30, 31–45, 46–64,
and 65 years or older); insurance status (commercial, Medicare,
Medicaid, self-pay, unknown); and geographic region (northeast,
south, midwest, west).
Analysis
Population characteristics describing the data were evaluated.
The number and proportion of patients who developed each
cardiometabolic risk factor during the observation period were
calculated overall and by baseline BMI. Four binary logistic
regression models were utilized to estimate the adjusted odds of
developing each of the four cardiometabolic risk factors post-
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index date by baseline BMI category. In an effort to isolate the
impact of baseline BMI on the development of risk factors, we
adjusted the models for potential confounding factors (age,
gender, insurance status, and geographic region). Similarly, the
odds of developing a speciﬁc number (0–4) of risk factors post–
index date by BMI category were estimated using a multinomial
logistic regression model, adjusting for the same independent
variables as was done for the individual risk factor models. The
general form of the model is the following:
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where ln is the natural log; Y is the outcome variable or speciﬁc
risk factor, and takes on values of 0, 1, 2, 3, or 4; k is the outcome
variable category and takes on value of 1 when the outcome is
binary, and values of 1, 2, 3, or 4 when the outcome is poly-
chotomous; Pr is the probability, BMI is body mass index and
takes on value of 1 when BMI > 27 kg/m2, and 0 when
BMI  27 kg/m2, with BMI  27 kg/m2 being the reference cat-
egory; gender takes on value of 1 when male, with female as the
reference category; agecat2, agecat3, and agecat4 are age catego-
ries of 31 to 45 years, 46 to 64 years, and 65 years or greater,
respectively, with age category of 18 to 30 years being the refer-
ence; insurtype2, insurtype3, insurtype4, and insurtype5 repre-
sent Medicare, Medicaid, self-pay, and unknown categories,
respectively, with commercial insurance being the reference cat-
egory; geogregion2, geogregion3, and geogregion4 represent
south, midwest, and west regions of the United States, respec-
tively, with northeast being the reference category; and b, s are
the parameters to be estimated.
All statistical tests were performed using Stata SE v. 9
(College Station, TX) and SAS v. 9 (SAS Institute, Cary, NC).
Results
Figure 1 illustrates identiﬁcation of the study population. Of the
initial GE data set of 3,301,897 patients, 3,216,092 were 18
years or older. Of these, 1,110,718 had a BMI measurement at
395 days or more after the ﬁrst activity date. Applying a
minimum 5-year activity after index date and baseline BMI
greater than 18 kg/m2 resulted in 70,375 people. Of these,
18,372 subjects did not have any of the four cardiometabolic risk
factors at baseline. Thus, the ﬁnal study population for analysis
consisted of 18,372 subjects, of whom 6,906 (37.6%) were obese
(BMI > 27 kg/m2) and 11,466 (62.4%) had a normal weight
(BMI  27 kg/m2) (Fig. 1).
Descriptive Results
Descriptive characteristics for the study population are shown in
Table 1. Approximately 38% had a baseline BMI > 27 kg/m2.
The study population was 29.3% male with a mean (standard
deviation) age of 43.5 (14.9) years (Table 1). A total of 10.9%
of the population was 65 years or older. The study population
had a mean (SD) BMI of 26.6 kg/m2 (5.9). The mean BMI (SD)
of those with BMI < 27 kg/m2 and those with BMI > 27 kg/m2
was 23.2 kg/m2 (2.2) and 32.3 kg/m2 (5.6), respectively.
Table 2 provides information on the distribution of risk
factors by BMI, demonstrating that a higher proportion of
patients fell in the obese (BMI > 27 kg/m2) category when a
speciﬁc risk factor developed as compared to when the risk factor
did not develop.
Table 3 reports the distribution of count of risk factors (0–4)
by BMI. The proportion of patients in the obese group
(BMI > 27 kg/m2) increased as the count of incident risk factors
increased. Approximately, 57% of patients developed at least one
new risk factor; 38% developed one new risk factor, of whom
41% had a baseline BMI > 27 kg/m2; 13% developed two risk
factors, of whom 52% had a baseline BMI > 27 kg/m2; 5%
developed three risk factors, of whom 65% had a baseline
BMI > 27 kg/m2; and 1% developed four new risk factors, of
whom 82% had a baseline BMI > 27 kg/m2.
Regression Results
As stated earlier, we estimated a separate logistic regression
model for each of the incident cardiometabolic risk factors, and
one model for the count of incident risk factors. Tables 4–7 show
that adjusted odds of developing a cardiometabolic risk factor
were greater for those with baseline BMI > 27 kg/m2 relative to
those with baseline BMI  27 kg/m2 for each of the four risk
factors examined, ranging from 2.1 (95% CI 1.9–2.3) for
elevated triglycerides, 2.2 (95% CI 2.1–2.4) for hypertension, 2.2
(95% CI 2.0–2.4) for low HDL-C, and to 2.3 (95% CI 2.0–2.7)
for diabetes. Further, male gender and age were signiﬁcantly
associated with an increased risk of developing all four risk
factors.
Patients age ≥ 18 years old on first
activity date
N=3,216,092 (97.4%)
With BMI Reading >=395 Days Post 
First Activity Date N=1,110,718 
(34.5%)
Baseline BMI> 18 kg/m2
N=91,034 (99.2%)
BMI <= 27kg/m2
N=11,466  (62.4%)
BMI > 27kg/m2
N=6906 (37.6%)
GE Population 1996 - 2005
N=3,301,897
With Follow-up BMI
N=70,375 (77.3%)
Minimum 5 Yr Activity Post Index Date
N=91,802 (8.3%)
Without Prevalence of Risk Factors
N=18,372 (26.1%)
Figure 1 Study population identiﬁcation. (Note:The percentages in each box
of the ﬂowchart are of the step above in the chart.)
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The adjusted odds of developing a speciﬁc number of risk
factors was greater when baseline BMI was greater than
27 kg/m2 relative to when BMI was less than or equal to 27 kg/
m2, with the odds increasing with each additional number of new
risk factors (Table 8). The odds of developing one new risk factor
were 1.9 (95% CI 1.8–2.1) for baseline BMI > 27 kg/m2 relative
to baseline BMI  27 kg/m2, increasing to 7.9 (95% CI 5.9–
10.5) for developing four new risk factors.
Table 1 Baseline characteristics by baseline BMI 27 or >27 kg/m2 (N = 18,372)
Total BMI 27 kg/m2 BMI > 27 kg/m2
N (%) N (%) N (%)
N 18,372 11,466 6,906
Mean age (SD) (years) 43.5 (14.9) 43.3 (15.3) 43.9 (14.3)
18–30 3,833 (20.9) 2,531 (22.1) 1,302 (18.9)
31–45 7,328 (39.9) 4,565 (39.8) 2,763 (40.0)
46–64 5,207 (28.3) 3,059 (26.7) 2,148 (31.1)
65+ 2,004 (10.9) 1,311 (11.4) 693 (10.0)
Gender
Male 5,376 (29.3) 2,901 (25.3) 2,475 (35.8)
Insurance type
Commercial 10,516 (57.2) 6,445 (56.2) 4,071 (58.9)
Medicaid 2,207 (12.0) 1,373 (12.0) 834 (12.1)
Medicare 214 (1.2) 123 (1.1) 91 (1.3)
Self-pay 306 (1.7) 218 (1.9) 88 (1.3)
Unknown 5,129 (27.9) 3,307 (28.8) 1,822 (26.4)
Region
Northeast 5,377 (29.3) 3,280 (28.6) 2,097 (30.4)
Southeast 2,400 (13.1) 1,396 (12.2) 1,004 (14.5)
Midwest 8,211 (44.7) 5,178 (45.2) 3,033 (43.9)
West 2,384 (13.0) 1,612 (14.1) 772 (11.2)
BMI, body mass index.
Table 2 Distribution of risk factors developed by BMI*
Total Without risk factor With risk factor
N (%) N (%) N (%)
Elevated triglycerides
BMI 27 kg/m2 11,466 (62.4) 10,771 (64.2) 695 (43.6)
BMI > 27 kg/m2 6,906 (37.6) 6,007 (35.8) 899 (56.4)
Total 18,372 16,778 1,594
Low HDL-C
BMI 27 kg/m2 11,466 (62.4) 9,566 (66.8) 1,900 (46.9)
BMI > 27 kg/m2 6,906 (37.6) 4,758 (33.2) 2,148 (53.1)
Total 18,372 14,324 4,048
Hypertension
BMI 27 kg/m2 11,466 (62.4) 6,910 (71.1) 4,556 (52.7)
BMI > 27 kg/m2 6,906 (37.6) 2,815 (28.9) 4,091 (47.3)
Total 18,372 9,725 8,647
Type 2 diabetes
BMI 27 kg/m2 11,466 (62.4) 11,085 (63.5) 381 (41.8)
BMI > 27 kg/m2 6,906 (37.6) 6,376 (36.5) 530 (58.2)
Total 18,372 17,461 911
*Elevated triglycerides: triglyceride 150 mg/dl, use of ﬁbrates, or ICD-9 code of 272.1. Low HDL-C: HDL-C < 40 mg/dl in men or <50 mg/dl in women, or use niacin. Hypertension: two blood
pressure readings 130/85 mmHg, use of an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, calcium channel blockers, beta-blocker, thiazide diuretic, vasodilator,
ﬁxed-dose antihypertensive combination, or ICD-9 code of 401.x.Type 2 diabetes: fasting blood glucose level 126 mg/dl use of sulfonylureas, metformin, thiazolidinediones, meglitinides, alpha
glucosidase inhibitors, ﬁxed-dose antidiabetic combinations, or ICD-9 code 250.x0 or 250.x2.
BMI, body mass index; HDL-C, high-density lipoprotein cholesterol.
Table 3 Count of patients by development of risk factor
Total BMI 27 kg/m2 BMI > 27 kg/m2
N % of
total
n % with risk
factor*
n % with risk
factor*18,372 11,466 6,906
Count of risk factors
0 7,848 42.7 5,796 73.9 2,052 26.1
1 7,048 38.4 4,172 59.2 2,876 40.8
2 2,442 13.3 1,164 47.7 1,278 52.3
3 868 4.7 304 35.0 564 65.0
4 166 0.9 30 18.1 136 81.9
*Shown as percent of total number of subjects with 0, 1, 2, 3, or 4 risk factors(s).
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Table 4 Adjusted odds ratio for patients with elevated triglycerides post–index date by BMI categories for baseline BMI > 27 kg/m2 versus baseline
BMI 27 kg/m2 (N = 18,372, events = 1,574)
Variable
Unadjusted
OR 95% CI
Adjusted
OR 95% CI
Baseline BMI > 27 kg/m2 (ref 27 kg/m2) 2.3* (2.1, 2.6) 2.1* (1.9, 2.3)
Gender (ref = female) 2.3* (2.1, 2.6) 2.0* (1.8, 2.2)
Age (ref = 18–30) (years)
31–45 2.7* (2.2, 3.3) 2.6* (2.1, 3.2)
46–64 4.5* (3.7, 5.5) 4.1* (3.4, 5.0)
65+ 3.8* (3.0, 4.7) 4.3* (3.3, 5.6)
Insurance status (ref commercial)
Medicare 1.6* (1.3, 1.8) 1.2 (1.0, 1.5)
Medicaid 0.9 (0.5, 1.6) 1.1 (0.6, 1.8)
Self-pay 1.0 (0.6, 1.5) 1.2 (0.7, 1.9)
Unknown 1.6* (1.5, 1.8) 2.0* (1.7, 2.2)
Geographic region (ref northeast)
South 1.0 (0.8, 1.1) 1.0 (0.8, 1.2)
Midwest 0.9 (0.8, 1.0) 0.7* (0.6, 0.8)
West 0.4* (0.3, 0.5) 0.3* (0.2, 0.4)
*Signiﬁcant at P < 0.05.
The c-statistic for the adjusted model was 0.72 (95% CI = 0.71–0.73).
BMI, body mass index; OR, odds ratio; CI, conﬁdence interval.
Table 5 Adjusted odds ratio for patients with low HDL-C post–index date by BMI categories for baseline BMI > 27 kg/m2 versus baseline
BMI 27 kg/m2 (N = 18,372, events = 4,048)
Variable
Unadjusted
OR 95% CI
Adjusted
OR 95% CI
Baseline BMI > 27 kg/m2 (ref 27 kg/m2) 2.3* (2.1, 2.4) 2.2* (2.0, 2.4)
Gender (ref = female) 1.5* (1.4, 1.6) 1.3* (1.2, 1.4)
Age (ref = 18–30) (years)
31–45 1.6* (1.5, 1.8) 1.6* (1.4, 1.7)
46–64 1.8* (1.6, 2.0) 1.6* (1.4, 1.8)
65+ 1.7* (1.4, 1.9) 1.5* (1.2, 1.7)
Insurance status (ref commercial)
Medicare 1.2* (1.1, 1.3) 1.2* (1.0, 1.3)
Medicaid 0.7 (0.5, 1.0) 0.8 (0.6, 1.2)
Self-pay 0.7* (0.5, 1.0) 0.7 (0.5, 1.0)
Unknown 0.9* (0.8, 0.9) 0.9 (0.8, 1.0)
Geographic region (ref northeast)
South 0.5* (0.5, 0.6) 0.5* (0.5, 0.6)
Midwest 0.8* (0.7, 0.8) 0.8* (0.7, 0.9)
West 0.7* (0.6, 0.7) 0.6* (0.6, 0.7)
*Signiﬁcant at P < 0.05.
The c-statistic for the adjusted model was 0.64 (95% CI = 0.63–0.65).
HDL-C, high-density lipoprotein cholesterol; BMI, body mass index; OR, odds ratio; CI, conﬁdence interval.
Table 6 Adjusted odds ratio for patients with hypertension post–index date by BMI categories for baseline BMI > 27 kg/m2 versus baseline
BMI 27 kg/m2 (N = 18,372, events = 8,647)
Variable
Unadjusted
OR 95% CI
Adjusted
OR 95% CI
Baseline BMI > 27 kg/m2 (ref 27 kg/m2) 2.2* (2.1, 2.3) 2.2* (2.1, 2.4)
Gender (ref = female) 1.8* (1.7, 1.9) 1.4* (1.3, 1.5)
Age (ref = 18–30) (years)
31–45 1.4* (1.2, 1.5) 1.3* (1.2, 1.4)
46–64 2.5* (2.3, 2.8) 2.3* (2.1, 2.6)
65+ 6.1* (5.4, 6.9) 4.9* (4.2, 5.7)
Insurance status (ref commercial)
Medicare 3.0* (2.7, 3.3) 1.4* (1.2, 1.6)
Medicaid 1.2 (1.0, 1.6) 1.5* (1.1, 2.0)
Self-pay 0.8 (0.6, 1.0) 1.0 (0.8, 1.2)
Unknown 0.8* (0.7, 0.8) 0.8* (0.7, 0.9)
Geographic region (ref northeast)
South 0.9* (0.8, 1.0) 1.0 (0.9, 1.1)
Midwest 0.8* (0.7, 0.8) 0.8* (0.7, 0.9)
West 1.3* (1.2, 1.4) 0.9 (0.8, 1.0)
*Signiﬁcant at P < 0.05.
The c-statistic for the adjusted model was 0.70 (95% CI = 0.69–0.71).
BMI, body mass index; OR, odds ratio; CI, conﬁdence interval.
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Analysis Using BMI of 30 kg/m2 as Cutoff
We also conducted analyses by recategorizing the study cohort by
baseline BMI. Speciﬁcally, we categorized those with baseline
BMI  30 kg/m2 as “normal weight,” and those with baseline
BMI > 30 kg/m2 as “obese.” We performed these analyses to
conﬁrm that our main results using a cutoff of BMI of 27 kg/m2
hold true when using the standard deﬁnition of obesity,
BMI > 30 kg/m2, as a cutoff point. We found the results in the
analyses using BMI of 30 kg/m2 as cutoff to be similar to those
using BMI of 27 kg/m2 as cutoff. All of the point estimates for
both individual cardiometabolic risk factor and count of risk
factor models were statistically signiﬁcant. Adjusted odds ratios
for individual risk factors ranged from 2.8 for diabetes to 2.1 for
elevated triglycerides. Further, adjusted odds ratios for the count
of risk factor model ranged from 2.1 for one risk factor to 8.5 for
four risk factors. These results provide a further validation of our
main results reported earlier.
Discussion
This retrospective cohort analysis of 18,372 geographically
diverse ambulatory adult subjects assessed the association
between baseline BMI and subsequent development of four other
cardiometabolic risk factors—elevated triglycerides, low HDL-C,
hypertension, and type 2 diabetes—over at least 5 years of clini-
cal follow-up in an ambulatory setting.
This study found that baseline BMI > 27 kg/m2 was associ-
ated with the subsequent development of all examined risk
factors, with adjusted odds increasing 110% for elevated triglyc-
erides, 130% for diabetes, and 120% for low HDL-C and hyper-
tension (P < 0.05 for all). Similarly, baseline BMI > 27 kg/m2 was
associated with an increase in the number of new risk factors
that developed over time. Thus, patients with baseline BMI >
27 kg/m2 were more likely to have a single or multiple incident
risk factors over the follow-up period than were patients with
baseline BMI  27 kg/m2. The likelihood of developing multiple
Table 7 Adjusted odds ratio for patients with diabetes post–index date by BMI categories for baseline BMI > 27 kg/m2 versus baseline BMI 27 kg/m2
(N = 18,372, events = 911)
Variable
Unadjusted
OR 95% CI
Adjusted
OR 95% CI
Baseline BMI > 27 kg/m2 (ref 27 kg/m2) 2.4* (2.1, 2.8) 2.3* (2.0, 2.7)
Gender (ref = female) 2.1* (1.9, 2.4) 1.6* (1.4, 1.9)
Age (ref = 18–30) (years)
31–45 1.1 (0.9, 1.4) 1.1 (0.8, 1.3)
46–64 2.0* (1.6, 2.5) 1.7* (1.3, 2.1)
65+ 4.8* (3.8, 6.1) 3.5* (2.6, 4.6)
Insurance status (ref commercial)
Medicare 3.3* (2.8, 3.8) 1.6* (1.3, 2.0)
Medicaid 1.0 (0.5, 2.0) 1.0 (0.5, 2.1)
Self-pay 0.9 (0.5, 1.6) 1.1 (0.6, 2.1)
Unknown 1.3 (1.1, 1.5) 1.3* (1.1, 1.6)
Geographic region (ref northeast)
South 1.3* (1.1, 1.6) 1.4* (1.1, 1.8)
Midwest 1.0 (0.9, 1.2) 0.9 (0.8, 1.1)
West 1.5* (1.2, 1.8) 0.9 (0.7, 1.2)
*Signiﬁcant at P < 0.05.
The c-statistic for the adjusted model was 0.72 (95% CI = 0.70–0.74).
BMI, body mass index; OR, odds ratio; CI, conﬁdence interval.
Table 8 Adjusted odds ratio† for patients developing a speciﬁc number of risk factors (relative to developing no risk factors) for baseline BMI > 27 kg/m2
versus 27 kg/m2 (N = 18,372)
Variable
One risk factor Two risk factors Three risk factors Four risk factors
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Baseline BMI > 27 kg/m2 (ref 27 kg/m2) 1.9* (1.8, 2.1) 3.1* (2.8, 3.4) 4.9* (4.3, 5.7) 7.9* (5.9, 10.5)
Gender (ref = female) 1.4* (1.3, 1.5) 1.8* (1.6, 2.0) 2.1* (1.8, 2.4) 2.9* (2.3, 3.8)
Age (ref = 18–30) (years)
31–45 1.3* (1.2, 1.4) 1.8* (1.5, 2.0) 2.9* (2.2, 3.8) 2.2* (1.3, 3.7)
46–64 2.0* (1.8, 2.2) 3.1* (2.6, 3.6) 6.1* (4.6, 8.0) 6.2* (3.8, 10.2)
65+ 3.4* (2.8, 4.0) 7.4* (5.9, 9.1) 14.3* (10.1, 20.2) 15.5* (8.5, 28.4)
Insurance status (ref commercial)
Medicare 1.4* (1.2, 1.6) 1.6* (1.4, 2.0) 1.7* (1.3, 2.2) 2.3* (1.5, 3.5)
Medicaid 1.3 (0.9, 1.7) 0.8 (0.5, 1.4) 1.6 (0.8, 3.1) 3.0* (1.0, 8.5)
Self-pay 1.0 (0.8, 1.3) 0.9 (0.6, 1.3) 0.6 (0.3, 1.4) 1.4 (0.4, 4.5)
Unknown 0.7* (0.7, 0.8) 0.9 (0.8, 1.1) 1.3* (1.1, 1.5) 2.0* (1.4, 2.7)
Geographic region (ref northeast)
South 0.9 (0.8, 1.0) 0.7* (0.6, 0.8) 0.7* (0.6, 0.9) 0.7 (0.4, 1.0)
Midwest 0.8* (0.7, 0.8) 0.7* (0.6, 0.7) 0.6* (0.5, 0.7) 0.7* (0.5, 0.9)
West 1.0 (0.9, 1.1) 0.8* (0.7, 0.9) 0.4* (0.3, 0.5) 0.2* (0.1, 0.3)
*Signiﬁcant at P < 0.05.
†Multinomial logistic regression.
BMI, body mass index; OR, odds ratio; CI, conﬁdence interval.
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risk factors, relative to developing no risk factors, increased
dramatically for BMI > 27 kg/m2, with the risk rising with the
number of incident risk factors, thereby magnifying their overall
cardiometabolic risk.
The association between an above normal body weight and
the incidence of cardiovascular risk factors has been demon-
strated in several cohort studies. An analysis based on the
Framingham Heart Study found the risk of developing hyperten-
sion was two and a half times higher (relative risk [RR] 2.63;
95% CI 2.20–3.15) for obese women (BMI  30 kg/m2), and
more than two times higher (RR 2.23; 95% CI 1.75–2.84) for
obese men than individuals of normal weight; the risk of devel-
oping type 2 diabetes was 36% higher in obese women (RR 1.36;
95% CI 1.03–1.78), and 85% higher in obese men (RR 1.85;
95% CI 1.31–2.26) [16]. Similarly, the San Antonio Heart Study
found an association between BMI and the development of type
2 diabetes [17], with each standard deviation increase in weight
with increasing odds of developing type 2 diabetes by 51% in
women (OR 1.51; 95% CI 1.21–1.90) and 69% in men (OR
1.69; 95% CI 1.07–2.65). A recent study by Ghandehari et al.
studied the association of obesity (BMI) and abdominal obesity
(waist circumference) with cardiometabolic risk factor burden
among adult Americans [18]. Mean levels of low-density lipo-
protein cholesterol, systolic and diastolic blood pressure, fasting
glucose, and C-reactive protein increased, and HDL-C decreased
(P < 0.001) as BMI and waist circumference increased [18]. Of
those with high waist circumference, 25–35% had 3 cardio-
metabolic risk factors.
This study is unique in that it was speciﬁcally designed to
evaluate the development of cardiometabolic risk using a large
longitudinal, nationally representative EMR database receiving
treatment in an ambulatory care setting. This study demonstrates
a signiﬁcant association of subsequent development of new car-
diometabolic risk factors among patients with baseline BMI of
>27 kg/m2. This is the same cutoff used by NIH guidelines for
treatment with weight loss agents in addition to diet and physical
activity in overweight patients with other cardiovascular risk
factors [11]. Results were similar in post hoc analyses when the
study cohorts were recategorized with baseline BMI  30 kg/m2
as “normal weight,” and those with baseline BMI > 30 kg/m2 as
“obese.”
In contrast to much of the related literature that evaluates
BMI or weight and the prevalence of additional risk factors, this
study was conducted in routine community practice settings
drawn from a major EMR research database. In addition, this is
one of a small number of studies that evaluated the association
between BMI at a given point in time and the development of
new cardiometabolic risk factors over a relatively long period of
time (5–8.5 years). The focus on an ambulatory care setting
provides insight for primary care physicians about the likelihood
of their overweight and obese patients developing other cardi-
ometabolic risk factors.
The results of this study are also important from a policy
perspective. Investment in shorter-term weight loss strategies
may delay or avoid the development of risk factors associated
with greater costs for a health plan. From a societal perspective,
it is apparent that obesity may lead to increase in cardiometa-
bolic risk over time. These complications not only impact
national direct costs, but also impact indirect costs associated
with quality of life and productivity.
Limitations
This study has a number of limitations. First, the use of an EMR
database may contain errors of omission and commission, which
is a ubiquitous challenge when conducting real-world studies
based on secondary data. First, patient race was missing in almost
two-thirds of the study population, thus it was not included as an
independent variable. In addition, having multiple measures indi-
cating the presence of a risk factor or to conﬁrm BMI to address
concerns of coding errors was not required in this study. Never-
theless, coding errors that could lead to misclassiﬁcation are likely
to be random, and thus not expected to bias study ﬁndings.
Lack of documentation of diagnosis and other clinical data
may be of greater concern. Thus, multiple data elements were
utilized to identify the presence of cardiometabolic risk factors
including diagnosis codes, prescription drug orders, and labora-
tory values in an effort to reduce false negatives. Similarly, BMI
is not recorded for every patient in the EMR, thus for this study
only those patients with BMI readings were included. This inclu-
sion requirement may have introduced a bias as physicians may
be more likely to measure height so that a BMI can be calculated
in patients who are obese compared with normal-weight
patients. Further, the possibility that patients with high BMI are
more likely to receive lab tests and thus are more likely to be
“diagnosed” may also have introduced a bias increasing the
likelihood of capturing incidence of risk factors for the obese
group. Thus, because of clinical data capture and reporting
biases, this study may overestimate the association between
obesity and the development of cardiometabolic risk factors.
The core outcome variable in this study was obesity, as deter-
mined by BMI. Although other indicators such as waist circum-
ference and waist–hip ratio have been shown to be equivalent
[15] or better predictors than BMI of cardiovascular risk factors
[18], they are generally not accessible in insurance claims or
medical record databases. Likewise, physicians are less likely to
measure, and patients are less likely to associate an increase in
waist circumference with increased cardiometabolic risk [19],
and therefore information based on BMI may be more clinically
relevant.
Finally, the minimum study period of 5 years may seem
limited in terms of assessing the risk of a population developing
cardiometabolic risk factors. We used a 5-year minimum as it
exacted a balance between the amount of time patients were
followed in the EMR and in obtaining a sufﬁcient number of
patients to evaluate study outcomes.
Conclusions
The study highlighted that obese patients are more likely to
develop cardiometabolic risk factors than those with normal
weight. Speciﬁcally, baseline overweight or obesity (BMI > 27 kg/
m2) was found to be signiﬁcantly associated with subsequent
development of individual, as well as multiple cardiometabolic
risk factors in a real-life ambulatory care setting. Future research
should examine the impact of prevention of obesity and reduc-
tion of weight and obesity on development of cardiometabolic
risk factors. A further extension of research is to explore the
extent of effects of decreases in cardiometabolic risk factors on
reduction in cardiovascular disease-related morbidity and mor-
tality. If this link is established, then weight loss may reduce
adverse clinical events and associated health-care costs.
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